The observations are related to the company's laboratory practices and staff training, which may lead to more severe warnings or even an import ban if not addressed properly. "Fast resolution of the issue is important, as Ratlam facility is very important for IPCA Labs because it supplies API both to Silvassa and Indore plant and they have voluntarily stopped shipments from that facility. But if these issues are not taken care of, there is a possibility of a warning letter or an import ban by USFDA," a report by Angel Broking said. As of FY2014, the US market has contributed sales of Rs 420 crore (12% of total sales) for IPCA Labs. Sales of the company are expected to be hit with a loss of Rs 150 crore in the next six months, according to company officials. The company expects to address the FDA concerns in about four to six months.